In today’s briefing:
- Why Is LG CNS One of the Hottest Stocks in Korea in the Past One Month? Answer: Stablecoin Platform
- Doosan Enerbility (034020.KQ) – Nuclear-Led Transition with Strong Visibility, But Valuation Full
- Latest Borrow (Net Short Interest) To Float Ratios — Screening a Starter Basket for Short Flow
- Lucror Analytics – Morning Views Asia
- SK Bioscience (302440 KS): Dual Engines Led Growth Strategy Is on Track; Solid 1Q25 Performance
Why Is LG CNS One of the Hottest Stocks in Korea in the Past One Month? Answer: Stablecoin Platform
- LG CNS has been one of the hottest stocks in the Korean stocks market in the past one month (up 87%), sharply outperforming KOSPI.
- The biggest driver of LG CNS’s share price in the past month has been that this company has the potential to become a leading stablecoin platform in Korea.
- Many investors believe that LG CNS has the expertise in blockchain/AI/cryptocurrency backend solutions to become one of the leading Won based stablecoin platforms in Korea.
Doosan Enerbility (034020.KQ) – Nuclear-Led Transition with Strong Visibility, But Valuation Full
- Margins have improved steadily since FY2020, but bottom-line gains remain volatile due to non-operating drags.
- Backlog at Record Highs; Nuclear a Key Differentiator: ₩20.1 tn order book, rising SMR traction, and global nuclear wins position Doosan as a strategic supplier.
- Structural Tailwinds Priced In: While medium-term growth looks strong, premium multiples (~28x EV/EBITDA) suggest limited room for execution missteps.
Latest Borrow (Net Short Interest) To Float Ratios — Screening a Starter Basket for Short Flow
- Dropped an Excel below with all names showing borrow as of today’s close — includes short interest and borrow-to-float using latest float data.
- Tables below flag names with borrow-to-float >4% (>3% for small caps) and plenty of unused borrow — solid candidates for potential short flow.
- Not auto-shorts — still need basic checks. But with borrow rising, this set looks like a solid starter basket to watch for short flow.
Lucror Analytics – Morning Views Asia
- In today’s Morning Views publication we comment on developments of the following high yield issuers: SK Hynix
- Front-end UST yields declined on Friday, on the back of Fed Governor Christopher Waller’s comments that a rate cut could come as early as July. The UST curve bull steepened, with the yield on the 2Y UST falling 3 bps to 3.91%, while that on the 10Y UST declined 1 bp to 4.38%.
- Equities retreated amid escalating tensions in the Middle East. In addition, semiconductor stocks fell after WSJ reported that the US could revoke export waivers for Western chipmakers to manufacture in China.
SK Bioscience (302440 KS): Dual Engines Led Growth Strategy Is on Track; Solid 1Q25 Performance
- SK Bioscience (302440 KS) has initiated global Phase 3 clinical trial of GBP410, a 21-valent pneumococcal conjugate vaccine (PCV21) candidate, with topline result expected in 2027.
- IDT Biologika recorded revenue of KRW118B in 1Q25, up from KRW111B in 4Q24. Considering 1Q25 momentum, IDT seems to be on track to meet 2025 guidance of KRW410B.
- 1Q25 base business revenue increased 62% YoY to KRW36B. Operating loss of the base business narrowed to KRW26B from a loss of KRW28B in year-ago quarter.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
